Literature DB >> 22076847

Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

Adam M Huber1, Angela B Robinson, Ann M Reed, Leslie Abramson, Sharon Bout-Tabaku, Ruy Carrasco, Megan Curran, Brian M Feldman, Harry Gewanter, Thomas Griffin, Kathleen Haines, Mark F Hoeltzel, Josephine Isgro, Philip Kahn, Bianca Lang, Patti Lawler, Bracha Shaham, Heinrike Schmeling, Rosie Scuccimarri, Michael Shishov, Elizabeth Stringer, Julie Wohrley, Norman T Ilowite, Carol Wallace.   

Abstract

OBJECTIVE: To use consensus methods and the considerable expertise contained within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) organization to extend the 3 previously developed treatment plans for moderate juvenile dermatomyositis (DM) to span the full course of treatment.
METHODS: A consensus meeting was held in Chicago on April 23-24, 2010, involving 30 pediatric rheumatologists and 4 lay participants. Nominal group technique was used to achieve consensus on treatment plans that represented typical management of moderate juvenile DM. A preconference survey of CARRA, completed by 151 (56%) of 272 members, was used to provide additional guidance to the discussion.
RESULTS: Consensus was reached on timing and rate of steroid tapering, duration of steroid therapy, and actions to be taken if patients were unchanged, worsening, or experiencing medication side effects or disease complications. Of particular importance, a single consensus steroid taper was developed.
CONCLUSION: We were able to develop consensus treatment plans that describe therapy for moderate juvenile DM throughout the treatment course. These treatment plans can now be used clinically, and data collected prospectively regarding treatment effectiveness and toxicity. This will allow comparison of these treatment plans and facilitate the development of evidence-based treatment recommendations for moderate juvenile DM.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22076847      PMCID: PMC3315594          DOI: 10.1002/acr.20695

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  14 in total

1.  Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature.

Authors:  Mark H Ebell; Jay Siwek; Barry D Weiss; Steven H Woolf; Jeffrey Susman; Bernard Ewigman; Marjorie Bowman
Journal:  Am Fam Physician       Date:  2004-02-01       Impact factor: 3.292

2.  Defining comparative effectiveness research: the importance of getting it right.

Authors:  Harold C Sox
Journal:  Med Care       Date:  2010-06       Impact factor: 2.983

3.  Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

Authors:  Bryan R Luce; Judith M Kramer; Steven N Goodman; Jason T Connor; Sean Tunis; Danielle Whicher; J Sanford Schwartz
Journal:  Ann Intern Med       Date:  2009-06-30       Impact factor: 25.391

4.  The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.

Authors:  Nicolino Ruperto; Angela Pistorio; Angelo Ravelli; Lisa G Rider; Clarissa Pilkington; Sheila Oliveira; Nico Wulffraat; Graciela Espada; Stella Garay; Ruben Cuttica; Michael Hofer; Pierre Quartier; Jose Melo-Gomes; Ann M Reed; Malgorzata Wierzbowska; Brian M Feldman; Miroslav Harjacek; Hans-Iko Huppertz; Susan Nielsen; Berit Flato; Pekka Lahdenne; Harmut Michels; Kevin J Murray; Lynn Punaro; Robert Rennebohm; Ricardo Russo; Zsolt Balogh; Madeleine Rooney; Lauren M Pachman; Carol Wallace; Philip Hashkes; Daniel J Lovell; Edward H Giannini; Boel Andersson Gare; Alberto Martini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06-25       Impact factor: 4.794

5.  Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.

Authors:  A M Huber; B Lang; C M LeBlanc; N Birdi; R K Bolaria; P Malleson; I MacNeil; J A Momy; G Avery; B M Feldman
Journal:  Arthritis Rheum       Date:  2000-03

6.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.

Authors:  Adam M Huber; Edward H Giannini; Suzanne L Bowyer; Susan Kim; Bianca Lang; Carol B Lindsley; Lauren M Pachman; Clarissa Pilkington; Ann M Reed; Robert M Rennebohm; Lisa G Rider; Carol A Wallace; Brian M Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-02       Impact factor: 4.794

Review 7.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

Review 8.  Defining Clinical Improvement in Adult and Juvenile Myositis.

Authors:  Lisa G Rider; Edward H Giannini; Michael Harris-Love; Galen Joe; David Isenberg; Clarissa Pilkington; Peter A Lachenbruch; Frederick W Miller
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

Review 9.  Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.

Authors:  Nicolino Ruperto; Angelo Ravelli; Kevin J Murray; Daniel J Lovell; Boel Andersson-Gare; Brian M Feldman; Stella Garay; Wietse Kuis; Claudia Machado; Lauren Pachman; Anne-Marie Prieur; Lisa G Rider; Earl Silverman; Elena Tsitsami; Pat Woo; Edward H Giannini; Alberto Martini
Journal:  Rheumatology (Oxford)       Date:  2003-06-27       Impact factor: 7.580

Review 10.  International consensus on preliminary definitions of improvement in adult and juvenile myositis.

Authors:  Lisa G Rider; Edward H Giannini; Hermine I Brunner; Nicola Ruperto; Laura James-Newton; Ann M Reed; Peter A Lachenbruch; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2004-07
View more
  44 in total

Review 1.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 2.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 3.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

4.  Moving towards optimal therapy in paediatric rheumatology.

Authors:  Jay Mehta
Journal:  Nat Rev Rheumatol       Date:  2016-04       Impact factor: 20.543

5.  Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis.

Authors:  Sarah Ringold; Pamela F Weiss; Robert A Colbert; Esi Morgan DeWitt; Tzielan Lee; Karen Onel; Sampath Prahalad; Rayfel Schneider; Susan Shenoi; Richard K Vehe; Yukiko Kimura
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-07       Impact factor: 4.794

Review 6.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

7.  Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic.

Authors:  Kayla D Brown; Cristan Farmer; G Mark Freeman; Ellen J Spartz; Bahare Farhadian; Margo Thienemann; Jennifer Frankovich
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-07-11       Impact factor: 2.576

Review 8.  Improving care delivery and outcomes in pediatric rheumatic diseases.

Authors:  Julia G Harris; Catherine A Bingham; Esi M Morgan
Journal:  Curr Opin Rheumatol       Date:  2016-03       Impact factor: 5.006

9.  Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).

Authors:  Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura
Journal:  Clin Trials       Date:  2018-03-15       Impact factor: 2.486

Review 10.  Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions.

Authors:  Yongdong Zhao; Eveline Y Wu; Melissa S Oliver; Ashley M Cooper; Matthew L Basiaga; Sheetal S Vora; Tzielan C Lee; Emily Fox; Gil Amarilyo; Sara M Stern; Jeffrey A Dvergsten; Kathleen A Haines; Kelly A Rouster-Stevens; Karen B Onel; Julie Cherian; Jonathan S Hausmann; Paivi Miettunen; Tania Cellucci; Farzana Nuruzzaman; Angela Taneja; Karyl S Barron; Matthew C Hollander; Sivia K Lapidus; Suzanne C Li; Seza Ozen; Hermann Girschick; Ronald M Laxer; Fatma Dedeoglu; Christian M Hedrich; Polly J Ferguson
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-07-12       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.